Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Conditions:   Cutaneous Squamous Cell Carcinoma;   Cutaneous Squamous Cell Carcinoma of the Head and Neck
Intervention:   Drug: Cemiplimab-Rwlc
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Regeneron Pharmaceuticals
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 28, 2020 / by / in
Comments